NoLymIT : New Immunotherapies Against Lymphoma

Home > CALYM > NoLymIT : New Immunotherapies Against Lymphoma

Research topics & objectives

Identifying, at the single cell level, the mechanisms linked to lymphocyte exhaustion in lymphomas, particularly within innate immunity populations; identifying new therapeutic targets in the lymphoma microenvironment; generating a screening platform on primary tissue samples of patients cultivated in 3D, in order to offer personalised medicine.

Research topics

Characterisation of the resistance mechanisms linked to lymphocyte exhaustion in B-cell lymphomas, particularly via the expression of immune checkpoints, with the aim of improving treatments and progressing towards a personalised medicine.

Key words

Lymphoma, immunotherapies, innate immunity, immune checkpoint and ScRNAseq.

Camille Laurent Professor

INSERM UMR1037, Team no. 9

« Being a CALYM member allows us to join a state-of-the-art network in the field of lymphoma research. It also allows us to expand and reinforce our interactions with teams that are also specialised in lymphoma research, which makes it possible to conduct large-scale collaborative research. Being a CALYM member means an acknowledgement of status and participating in high-quality lymphoma research. »

 Pr Camille Laurent
Innovations thérapeutiques des lymphomes B Institut Carnot CALYM
Expertise

Expertise

  • Manipulation and immunophenotyping of lymphoma sub-populations of stem cells from patient lymph node tissues and blood
  • Generating 3D models
  • NGS capturing and ARN sequencing on single cells sequencing technologies (CITE-Seq, single cell RNASeq, Spatial transcriptomics,…),
  • Developing bioinformatics software, anatomic pathology, cell imaging (multiplexed IF)
  • Translational research.

Platforms and technical resources

  • The CRCT technological platform (Team 9 JJF/CL)
  • CeVi Platform in place at a site in Toulouse, with access to the CRB Cancer for frozen tumour samples
  • Access to the Pathology Department (Pr C Laurent) for fixed diagnostic samples and included in paraffin, with privileged access to the IHC/IF and IBISA Image Analysis (H&E, IHC, IF, FISH) Platforms with digital quantification programs (C Laurent)
  • Interaction with the Haematology Department (Pr L Ysebaert) to facilitate translational research.

TOP 5 of the latest scientific publications (basic research and clinical research)

Calym Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, Amara N, Adélaïde J, Guille A, Schiano JM, Tesson B, Traverse-Glehen A, Chenard MP, Mescam L, Moreau A, Chassagne-Clement C, Somja J, Escudié F, André M, Martin N, Lacroix L, Lemonnier F, Hamy AS, Reyal F, Bannier M, Oberic L, Prade N, Frénois FX, Beldi-Ferchiou A, Delfau-Larue MH, Bouabdallah R, Birnbaum D, Brousset P, Xerri L, Gaulard P.
Blood. 2020 Jan 30;135(5):360-370. Learn more
Calym Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes
Pizzolato G, Kaminski H, Tosolini M, Franchini DM, Pont F, Martins F, et al.
2019; 116:11906-11915. Learn more
Calym Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Rep
Franchini DM, Lanvin O, Tosolini M, Patras de Campaigno E, Cammas A, Péricart S, Scarlata CM, Lebras M, Rossi C, Ligat L, Pont F, Arimondo PB, Laurent C, Ayyoub M, Despas F, Lapeyre-Mestre M, Millevoi S, Fournié JJ.
2019 Jan 2;26(1):94-107.e7. Learn more
Calym EBV infection determines the immune hallmarks of plasmablastic lymphoma. Oncoimmunology
Gravelle P, Péricart S, Tosolini M, Fabiani B, Coppo P, Amara N, Traverse-Gléhen A, Van Acker N, Brousset P, Fournie JJ, Laurent C.
2018 Jul 30;7(10):e1486950. Learn more
Calym Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol
Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P.
2017 Jun 20;35(18):2008-2017. Learn more